proxyvotesnow.com
22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › FENNEC PHARMACEUTICALS INC. › 2024-2025

FENNEC PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

At FENNEC PHARMACEUTICALS INC.'s shareholder meeting held June 3, 2025, in the 2024-2025 proxy season, 87 asset managers reported how they voted in their SEC Form N-PX filings, covering 764 separate fund positions. Their filings are grouped here into 10 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — EXECUTIVE COMPENSATION To vote, on an advisory (non-binding) basis, on the compensation of the… — FENNEC PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 88% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: FENNEC PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2025.

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and FENNEC PHARMACEUTICALS INC.’s Form 8-K, filed June 3, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.

  • 10Reported items
  • 87Asset managers
  • 764Fund votes
  • June 3, 2025Meeting date

Results at a glance

Meeting of June 3, 2025: 9 items on FENNEC PHARMACEUTICALS INC.’s Form 8-K, filed June 3, 2025: 3 approved · 6 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore FENNEC PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by FENNEC PHARMACEUTICALS INC.

These tallies are FENNEC PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

FENNEC PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 3, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dr. Khalid Islam 13,432,561---- 304,7605,580,283 98%Not verified—
Elect Director: Chris A. Rallis 13,808,792---- 354,0995,580,283 97%Not verified—
Elect Director: Marco Brughera 13,807,501---- 355,3905,580,283 97%Not verified—
Elect Director: Jodi Cook 13,259,894---- 902,9975,580,283 94%Not verified—
Elect Director: Rostislav Raykov 13,432,561---- 730,3305,580,283 95%Not verified—
Elect Director: Jeffrey Hackman 13,495,309---- 687,5825,580,283 95%Not verified—
2. Resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration 19,673,487282-- 69,4050 99.9%Approved—
3. Resolution to vote on the advisory vote on executive compensation 12,110,5981,595,423456,870 --5,580,283 88%Approved—
4. Resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan 12,927,131776,907458,853 --5,580,283 94%Approved—

Source: FENNEC PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 3, 2025 — read the filing on EDGAR.

How asset managers voted at the FENNEC PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 87 asset managers that disclosed a FENNEC PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of FENNEC PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Jodi Cook

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 13,259,894WITHHELD: 902,997
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Dr. Jodi A. Cook

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jodi Cook”): 13,259,894 for, 902,997 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 1,607,878 for, 26,284 withheld.

FOR
FOR: 1,607,878WITHHOLD: 26,284
Largest asset managers voting on “ELECTION OF DIRECTORS: Dr. Jodi A. Cook” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
BlackRock540,9080 00For
Fidelity275,0530 00For
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC38,0820 00For
Equitable25,2510 07,830Mixed
Lincoln Financial18,9000 00For
Global X00 013,962Withhold
BRIDGEWAY FUNDS INC11,7000 00For
Northern Trust11,0850 00For
Legg Mason9,8100 00For
Bridge Builder Trust8,7140 00For
Brighthouse8,2860 00For
Pacific Life8,1440 00For
GPS Funds I7,8130 00For
Voya6,2620 00For
ProShares5,1800 00For
John Hancock4,7050 00For
AIG/SunAmerica3,1660 00For
MASTER INVESTMENT PORTFOLIO00 02,062Withhold
DWS1,7330 00For
Calvert00 01,499Withhold
State Street1,2320 00For
T. Rowe Price1,2270 00For
Franklin Templeton1,1220 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

2. Elect Director: Dr. Khalid Islam

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 13,432,561WITHHELD: 304,760
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Dr. Khalid Islam

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dr. Khalid Islam”): 13,432,561 for, 304,760 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 1,632,663 for, 1,499 withheld.

FOR
FOR: 1,632,663WITHHOLD: 1,499
Largest asset managers voting on “ELECTION OF DIRECTORS: Dr. Khalid Islam” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
BlackRock540,9080 00For
Fidelity275,0530 00For
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC38,0820 00For
Equitable33,0810 00For
Lincoln Financial18,9000 00For
Global X13,9620 00For
BRIDGEWAY FUNDS INC11,7000 00For
Northern Trust11,0850 00For
Legg Mason9,8100 00For
Bridge Builder Trust8,7140 00For
Brighthouse8,2860 00For
Pacific Life8,1440 00For
GPS Funds I7,8130 00For
Voya6,2620 00For
ProShares5,1800 00For
John Hancock4,7050 00For
AIG/SunAmerica3,1660 00For
MASTER INVESTMENT PORTFOLIO2,0620 00For
DWS1,7330 00For
Calvert00 01,499Withhold
State Street1,2320 00For
T. Rowe Price1,2270 00For
Franklin Templeton1,1220 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

3. Elect Director: Marco Brughera

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 13,807,501WITHHELD: 355,390
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Dr. Marco Brughera

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Marco Brughera”): 13,807,501 for, 355,390 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 1,630,340 for, 3,822 withheld.

FOR
FOR: 1,630,340WITHHOLD: 3,822
Largest asset managers voting on “ELECTION OF DIRECTORS: Dr. Marco Brughera” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
BlackRock540,9080 00For
Fidelity275,0530 00For
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC38,0820 00For
Equitable33,0810 00For
Lincoln Financial18,9000 00For
Global X13,9620 00For
BRIDGEWAY FUNDS INC11,7000 00For
Northern Trust11,0850 00For
Legg Mason9,8100 00For
Bridge Builder Trust8,7140 00For
Brighthouse8,2860 00For
Pacific Life8,1440 00For
GPS Funds I7,8130 00For
Voya6,2620 00For
ProShares5,1800 00For
John Hancock4,7050 00For
AIG/SunAmerica3,1660 00For
MASTER INVESTMENT PORTFOLIO00 02,062Withhold
DWS1,7330 00For
Calvert00 01,499Withhold
State Street1,2320 00For
T. Rowe Price1,2270 00For
Franklin Templeton1,1220 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

4. Elect Director: Chris A. Rallis

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 13,808,792WITHHELD: 354,099
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Mr. Chris A. Rallis

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Chris A. Rallis”): 13,808,792 for, 354,099 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 1,630,340 for, 3,822 withheld.

FOR
FOR: 1,630,340WITHHOLD: 3,822
Largest asset managers voting on “ELECTION OF DIRECTORS: Mr. Chris A. Rallis” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
BlackRock540,9080 00For
Fidelity275,0530 00For
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC38,0820 00For
Equitable33,0810 00For
Lincoln Financial18,9000 00For
Global X13,9620 00For
BRIDGEWAY FUNDS INC11,7000 00For
Northern Trust11,0850 00For
Legg Mason9,8100 00For
Bridge Builder Trust8,7140 00For
Brighthouse8,2860 00For
Pacific Life8,1440 00For
GPS Funds I7,8130 00For
Voya6,2620 00For
ProShares5,1800 00For
John Hancock4,7050 00For
AIG/SunAmerica3,1660 00For
MASTER INVESTMENT PORTFOLIO00 02,062Withhold
DWS1,7330 00For
Calvert00 01,499Withhold
State Street1,2320 00For
T. Rowe Price1,2270 00For
Franklin Templeton1,1220 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

5. Elect Director: Jeffrey Hackman

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 13,495,309WITHHELD: 687,582
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Mr. Jeff Hackman

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jeffrey Hackman”): 13,495,309 for, 687,582 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 1,634,162 for.

FOR
FOR: 1,634,162
Largest asset managers voting on “ELECTION OF DIRECTORS: Mr. Jeff Hackman” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
BlackRock540,9080 00For
Fidelity275,0530 00For
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC38,0820 00For
Equitable33,0810 00For
Lincoln Financial18,9000 00For
Global X13,9620 00For
BRIDGEWAY FUNDS INC11,7000 00For
Northern Trust11,0850 00For
Legg Mason9,8100 00For
Bridge Builder Trust8,7140 00For
Brighthouse8,2860 00For
Pacific Life8,1440 00For
GPS Funds I7,8130 00For
Voya6,2620 00For
ProShares5,1800 00For
John Hancock4,7050 00For
AIG/SunAmerica3,1660 00For
MASTER INVESTMENT PORTFOLIO2,0620 00For
DWS1,7330 00For
Calvert1,4990 00For
State Street1,2320 00For
T. Rowe Price1,2270 00For
Franklin Templeton1,1220 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

6. Elect Director: Rostislav Raykov

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 13,432,561WITHHELD: 730,330
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: ELECTION OF DIRECTORS: Mr. Rostislav Raykov

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Rostislav Raykov”): 13,432,561 for, 730,330 withheld, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 1,634,162 for.

FOR
FOR: 1,634,162
Largest asset managers voting on “ELECTION OF DIRECTORS: Mr. Rostislav Raykov” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
BlackRock540,9080 00For
Fidelity275,0530 00For
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC38,0820 00For
Equitable33,0810 00For
Lincoln Financial18,9000 00For
Global X13,9620 00For
BRIDGEWAY FUNDS INC11,7000 00For
Northern Trust11,0850 00For
Legg Mason9,8100 00For
Bridge Builder Trust8,7140 00For
Brighthouse8,2860 00For
Pacific Life8,1440 00For
GPS Funds I7,8130 00For
Voya6,2620 00For
ProShares5,1800 00For
John Hancock4,7050 00For
AIG/SunAmerica3,1660 00For
MASTER INVESTMENT PORTFOLIO2,0620 00For
DWS1,7330 00For
Calvert1,4990 00For
State Street1,2320 00For
T. Rowe Price1,2270 00For
Franklin Templeton1,1220 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

7. Resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan

Official resultCOMPENSATIONReported outcome: Approved

94% Approved · of votes cast

FOR 94%
FOR: 12,927,131AGAINST: 776,907
Details: description as filed, official tally, votes by 24 asset managers

Description as filed by funds: AMENDMENT TO 2020 EQUITY INCENTIVE PLAN To consider, and if deemed advisable, approve, an amendment to Fennec's 2020 Equity Incentive Plan.

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“4. Resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan”): 12,927,131 for, 776,907 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan was approved based on the following vote:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 24 asset managers below reported 893,884 for, 79,986 against.

FOR
FOR: 893,884AGAINST: 79,986
Largest asset managers voting on “AMENDMENT TO 2020 EQUITY INCENTIVE PLAN To consider, and if deemed advisable, approve, an amendment to Fennec'” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
Fidelity275,0530 00For
Equitable25,2517,830 00Mixed
Lincoln Financial018,900 00Against
BRIDGEWAY FUNDS INC011,700 00Against
Northern Trust11,0850 00For
Legg Mason09,810 00Against
Brighthouse08,286 00Against
Pacific Life8,1440 00For
Voya06,262 00Against
ProShares05,180 00Against
AIG/SunAmerica03,166 00Against
DWS01,733 00Against
Calvert01,499 00Against
State Street01,232 00Against
T. Rowe Price01,227 00Against
Franklin Templeton01,122 00Against
PENN SERIES FUNDS INC0700 00Against
Columbia Threadneedle0670 00Against
Nationwide5500 00For
Brinker Capital Destinations Trust0411 00Against
TIAA2610 00For
Guggenheim0216 00Against
Goldman Sachs042 00Against

8. Resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 12,927,131AGAINST: 776,907
Details: description as filed, official tally, votes by 8 asset managers

Description as filed by funds: AMENDMENT TO 2O2O EQUITY INCENTIVE PLAN - To consider, and if deemed advisable, approve, an amendment to Fennec's 2020 Equity Incentive Plan.

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“4. Resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan”): 12,927,131 for, 776,907 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The resolution to vote on the proposed amendment to the 2020 Equity Incentive Plan was approved based on the following vote:”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 8 asset managers below reported 647,774 for, 12,518 against.

FOR
FOR: 647,774AGAINST: 12,518
Largest asset managers voting on “AMENDMENT TO 2O2O EQUITY INCENTIVE PLAN - To consider, and if deemed advisable, approve, an amendment to Fenne” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock540,9080 00For
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC38,0820 00For
Global X13,9620 00For
Bridge Builder Trust8,7140 00For
GPS Funds I07,813 00Against
John Hancock04,705 00Against
MASTER INVESTMENT PORTFOLIO2,0620 00For

9. Resolution to vote on the advisory vote on executive compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

88% Approved · of votes cast

FOR 88%
FOR: 12,110,598AGAINST: 1,595,423
Details: description as filed, official tally, votes by 87 asset managers

Description as filed by funds: EXECUTIVE COMPENSATION To vote, on an advisory (non-binding) basis, on the compensation of the Corporation's named executive officers.

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“3. Resolution to vote on the advisory vote on executive compensation”): 12,110,598 for, 1,595,423 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 32 asset managers voting on “EXECUTIVE COMPENSATION To vote, on an advisory (non-binding) basis, on the compensation of the Corporation's n” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
BlackRock0540,908 00Against
Fidelity0275,053 00Against
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC038,082 00Against
Equitable7,83025,251 00Mixed
Lincoln Financial18,9000 00For
Global X13,9620 00For
BRIDGEWAY FUNDS INC011,700 00Against
Northern Trust11,0850 00For
Legg Mason09,810 00Against
Bridge Builder Trust08,714 00Against
Brighthouse08,286 00Against
Pacific Life08,144 00Against
GPS Funds I07,813 00Against
Voya06,262 00Against
ProShares05,180 00Against
John Hancock04,705 00Against
AIG/SunAmerica03,166 00Against
MASTER INVESTMENT PORTFOLIO2,0620 00For
DWS01,733 00Against
Calvert01,499 00Against
State Street1,2320 00For
T. Rowe Price01,227 00Against
Franklin Templeton01,122 00Against

Fund voting reports, all 32 managers: 674,029 for, 960,133 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 65 asset managers voting on “EXECUTIVE COMPENSATION To vote, on an advisory (non-binding) basis, on the compensation of the Corporation's n” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Southpoint Capital Advisors LP4,077,2140 00For
Solas Capital Management, LLC1,732,0450 00For
HARBERT FUND ADVISORS, INC.465,5680 00For
GEODE CAPITAL MANAGEMENT, LLC0279,232 00Against
BlackRock6,885255,095 00Against
State Street224,5441,453 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC0199,473 00Against
Northern Trust91,19594 00For
MELLON INVESTMENTS Corp63,7110 00For
Charles Schwab44,0460 00For
Bronte Capital Management Pty Ltd.32,3790 00For
STATE OF WISCONSIN INVESTMENT BOARD022,000 00Against
Vanguard12,9807,768 00Mixed
BRIDGEWAY CAPITAL MANAGEMENT, LLC011,700 00Against
FRANKLIN ADVISERS INC09,810 00Against
NEW YORK STATE COMMON RETIREMENT FUND9,7530 00For
Citadel9,0980 00For
Edward D. Jones & Co., L.P.8,9500 00For
T. Rowe Price08,717 00Against
WASHINGTON STATE INVESTMENT BOARD8,3930 00For
Rhumbline08,336 00Against
AllianceBernstein7,8300 00For
Goldman Sachs07,821 00Against
Invesco06,954 00Against
SEI6,4730 00For

Institutional-manager reports, all 65 managers: 6,818,375 for, 848,228 against. Showing the 25 largest; every one is in the interactive database (link above).

10. Resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 19,673,487AGAINST: 282
Details: description as filed, official tally, votes by 32 asset managers

Description as filed by funds: APPOINTMENT OF AUDITORS Appointment of Haskell & White LLP as the auditors of the Corporation for the year ending December 31, 2025 and authorizing the directors of the Corporation to fix their remuneration.

FENNEC PHARMACEUTICALS INC.’s own tally for this item (“2. Resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration”): 19,673,487 for, 282 against — passed, per its Form 8-K filed June 3, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 1,634,162 for.

FOR
FOR: 1,634,162
Largest asset managers voting on “APPOINTMENT OF AUDITORS Appointment of Haskell & White LLP as the auditors of the Corporation for the year end” at FENNEC PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard573,5400 00For
BlackRock540,9080 00For
Fidelity275,0530 00For
Charles Schwab44,0460 00For
QUANTITATIVE MASTER SERIES LLC38,0820 00For
Equitable33,0810 00For
Lincoln Financial18,9000 00For
Global X13,9620 00For
BRIDGEWAY FUNDS INC11,7000 00For
Northern Trust11,0850 00For
Legg Mason9,8100 00For
Bridge Builder Trust8,7140 00For
Brighthouse8,2860 00For
Pacific Life8,1440 00For
GPS Funds I7,8130 00For
Voya6,2620 00For
ProShares5,1800 00For
John Hancock4,7050 00For
AIG/SunAmerica3,1660 00For
MASTER INVESTMENT PORTFOLIO2,0620 00For
DWS1,7330 00For
Calvert1,4990 00For
State Street1,2320 00For
T. Rowe Price1,2270 00For
Franklin Templeton1,1220 00For

Showing the 25 largest of 32 asset managers. All 32 are in the interactive database (link above).

Largest FENNEC PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 27,618,743 shares outstanding at the time of that meeting.

Fund voting reports: top FENNEC PHARMACEUTICALS INC. shareholders by shares voted on “EXECUTIVE COMPENSATION To vote, on an advisory (non-binding) basis, on the compensation of the…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 2.08%
2BlackRock 1.96%
3Fidelity 1.00%
4Charles Schwab 0.16%
5QUANTITATIVE MASTER SERIES LLC 0.14%
6Equitable 0.12%
7Lincoln Financial 0.07%
8Global X 0.05%
9BRIDGEWAY FUNDS INC 0.04%
10Northern Trust 0.04%
Institutional-manager reports: top FENNEC PHARMACEUTICALS INC. shareholders by shares voted on “EXECUTIVE COMPENSATION To vote, on an advisory (non-binding) basis, on the compensation of the…”, 2024-2025
#Asset manager % of shares outstanding
1Southpoint Capital Advisors LP 14.76%
2Solas Capital Management, LLC 6.27%
3HARBERT FUND ADVISORS, INC. 1.69%
4GEODE CAPITAL MANAGEMENT, LLC 1.01%
5BlackRock 0.95%
6State Street 0.82%
7PARAMETRIC PORTFOLIO ASSOCIATES LLC 0.72%
8Northern Trust 0.33%
9MELLON INVESTMENTS Corp 0.23%
10Charles Schwab 0.16%

Reported FENNEC PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

FENNEC PHARMACEUTICALS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
Rosalind Advisors, Inc. 11.01% 13G
Kam Lawrence 10.14% 13G
Southpoint Master Fund, LP 9.94% 13G
Solas Capital Management, LLC 8.99% 13G
AIGH Capital Management LLC 7.17% 13G
BlackRock 4.53% 13F
DG Capital Management, LLC 4.04% 13G
Vanguard Group 3.49% 13F
State Street 1.22% 13F
Geode Capital 1.13% 13F

Percentages above are of 27,618,743 shares outstanding, as reported by FENNEC PHARMACEUTICALS INC. on its Form 10-Q dated May 9, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from FENNEC PHARMACEUTICALS INC.’s 10-Q dated May 9, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.

FENNEC PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

proxyvotesnow.com, “FENNEC PHARMACEUTICALS (FENC) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/fennec-pharmaceuticals-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.